Trials / Completed
CompletedNCT00535834
Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154
Data Analysis for 00-C-0154, A Randomized Phase II Study of a PSA-based Vaccine in Patients With Localized Prostate Cancer Receiving Standard Radiotherapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 48 (planned)
- Sponsor
- National Institutes of Health Clinical Center (CC) · NIH
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of blood in the laboratory from patients before and after treatment may help doctors learn more about the effects of the treatment on cells. PURPOSE: This clinical trial is studying samples collected from patients with localized prostate cancer who received treatment on clinical trial NCI-00-C-0154.
Detailed description
OBJECTIVES: Primary * Evaluate the formation of antibody complexes in serum samples taken before initiation of treatment and after completion of therapy in prostate cancer patients previously enrolled on clinical trial NCI-00-C-0154. * Evaluate immunologic response. Secondary * Clone the underlying tumor antigens discovered through SEREX. OUTLINE: Samples previously collected on clinical trial NCI-00-C-0154 (whole blood, serum, and peripheral mononuclear blood cells) are analyzed for immunologic responses and evidence of formation of anti-tumor antibodies. Western blot is used to detect any evidence of vaccine-induced autoantibody responses. If there is an indication of response, SEREX is used to clone the underlying antigens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | diagnostic procedure | |
| PROCEDURE | molecular diagnostic method | |
| PROCEDURE | protein expression analysis |
Timeline
- Completion
- 2011-03-01
- First posted
- 2007-09-26
- Last updated
- 2012-03-16
Source: ClinicalTrials.gov record NCT00535834. Inclusion in this directory is not an endorsement.